These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 2142480)

  • 1. Inhibition of the alternative C3 convertase and classical C5 convertase of complement by group A streptococcal M protein.
    Hong K; Kinoshita T; Takeda J; Kozono H; Pramoonjago P; Kim YU; Inoue K
    Infect Immun; 1990 Aug; 58(8):2535-41. PubMed ID: 2142480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
    Fearon DT
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of C5 convertase activity by properdin, factors B and H.
    Weiler JM
    Immunol Res; 1989; 8(4):305-15. PubMed ID: 2531781
    [No Abstract]   [Full Text] [Related]  

  • 4. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
    Waldo FB; Forristal J; Beischel L; West CD
    J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
    Gigli I; Fujita T; Nussenzweig V
    Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H.
    Horstmann RD; Sievertsen HJ; Knobloch J; Fischetti VA
    Proc Natl Acad Sci U S A; 1988 Mar; 85(5):1657-61. PubMed ID: 2964038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
    Medof ME; Kinoshita T; Nussenzweig V
    J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The inhibitory effect of factor J on the alternative complement pathway.
    González-Rubio C; Jiménez-Clavero MA; Fontán G; López-Trascasa M
    J Biol Chem; 1994 Oct; 269(42):26017-24. PubMed ID: 7929312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
    Sturtevant JE; Balber AE
    Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
    Sahu A; Isaacs SN; Soulika AM; Lambris JD
    J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activation of the alternative pathway C3 convertase by human plasma kallikrein.
    DiScipio RG
    Immunology; 1982 Mar; 45(3):587-95. PubMed ID: 6916710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).
    Seya T; Okada M; Matsumoto M; Hong KS; Kinoshita T; Atkinson JP
    Mol Immunol; 1991 Oct; 28(10):1137-47. PubMed ID: 1833639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
    Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
    J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restriction of the alternative pathway of human complement by intact Trypanosoma brucei subsp. gambiense.
    Devine DV; Falk RJ; Balber AE
    Infect Immun; 1986 Apr; 52(1):223-9. PubMed ID: 3633873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of classical C5 convertase in the complement system by factor H.
    Ito S; Tamura N
    Immunology; 1983 Dec; 50(4):631-5. PubMed ID: 6228516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b.
    Maillet F; Kazatchkine MD; Glotz D; Fischer E; Rowe M
    Mol Immunol; 1983 Dec; 20(12):1401-4. PubMed ID: 6558419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of the human complement regulators CFHR1 and factor H by streptococcal collagen-like protein 1 (Scl1) via their conserved C termini allows control of the complement cascade at multiple levels.
    Reuter M; Caswell CC; Lukomski S; Zipfel PF
    J Biol Chem; 2010 Dec; 285(49):38473-85. PubMed ID: 20855886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
    Pangburn MK; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C3b generation is affected by the structure of the O-antigen polysaccharide in lipopolysaccharide from salmonellae.
    Jimenez-Lucho VE; Joiner KA; Foulds J; Frank MM; Leive L
    J Immunol; 1987 Aug; 139(4):1253-9. PubMed ID: 2440949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.